Nicholas Investment Partners, LP Sage Therapeutics, Inc. Transaction History

Nicholas Investment Partners, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$58.41 - $89.06 $6.18 Million - $9.42 Million	-105,771 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$41.13 - $62.45 $4.35 Million - $6.61 Million	105,771 New	105,771 $6.47 Million
Q4 2019 Feb 13, 2020	SELL	$60.18 - $154.77 $3.6 Million - $9.25 Million	-59,761 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$140.29 - $189.96 $2.5 Million - $3.39 Million	-17,855 Reduced 23.0%	59,761 $8.38 Million
Q2 2019 Aug 09, 2019	SELL	$157.85 - $183.09 $404,411 - $469,076	-2,562 Reduced 3.2%	77,616 $14.2 Million
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $2.4 Million - $4.39 Million	26,815 Added 50.25%	80,178 $12.8 Million
Q4 2018 Feb 14, 2019	SELL	$81.94 - $139.71 $2.12 Million - $3.61 Million	-25,813 Reduced 32.6%	53,363 $5.11 Million
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $251,083 - $307,314	-1,818 Reduced 2.24%	79,176 $11.2 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $2.67 Million - $3.35 Million	19,048 Added 30.75%	80,994 $12.7 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $3.48 Million - $4.4 Million	22,894 Added 58.62%	61,946 $9.98 Million
Q4 2017 Feb 14, 2018	SELL	$60.72 - $167.34 $189,507 - $522,268	-3,121 Reduced 7.4%	39,052 $6.43 Million
Q3 2017 Nov 13, 2017	BUY	$61.4 - $88.52 $2.59 Million - $3.73 Million	42,173	42,173 $2.63 Million

218

48M

854K

195K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $361M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Nicholas Investment Partners, LP with notifications on news.